USANA Health Sciences, Inc. updated earnings guidance for the year 2023. Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.96 USD | -0.95% |
|
-5.31% | -16.12% |
05-07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
05-01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.12% | 857M | |
+9.79% | 7.89B | |
+2.60% | 7.2B | |
-2.68% | 5.75B | |
-8.03% | 3.64B | |
-14.39% | 3.42B | |
-15.43% | 1.16B | |
-28.11% | 1.1B | |
+5.08% | 906M | |
-13.46% | 828M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023